FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308743119> ?p ?o ?g. }

• W4308743119 endingPage "106264" @default.
• W4308743119 startingPage "106264" @default.
• W4308743119 abstract "Although the effective drugs or vaccines have been developed to prevent the spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), their efficacy may be limited for the viral evolution and immune escape. Thus, it is urgently needed to develop the novel broad-spectrum antiviral agents to control the coronavirus disease 2019 (COVID-19) global pandemic. The 3C-like protease (3CLpro) is a highly conserved cysteine proteinase that plays a pivotal role in processing the viral polyprotein to create non-structural proteins (nsps) for replication and transcription of SARS-CoV-2, making it an attractive antiviral target for developing broad-spectrum antiviral agents against SARS-CoV-2. In this study, we identified Thonzonium bromide as an inhibitor of SARS-CoV-2 3CLpro with an IC50 value of 2.04 ± 0.25 μM by fluorescence resonance energy transfer (FRET)-based enzymatic inhibition assay from the FDA-approved drug library. Next, we determined the inhibitory activity of Thonzonium bromide analogues against SARS-CoV-2 3CLpro and analyzed their structure–activity relationship (SAR). Interestingly, Thonzonium bromide showed better inhibitory activity than other analogues. Further fluorescence quenching assay, enzyme kinetics analysis, circular dichroism (CD) analysis and molecular docking studies showed that Thonzonium bromide inhibited SARS-CoV-2 3CLpro activity by firmly occupying the catalytic site and inducing conformational changes of the protease. In addition, Thonzonium bromide didn’t exhibit inhibitory activity on human chymotrypsin C (CTRC) and Dipeptidyl peptidase IV (DPP-IV), indicating that it had a certain selectivity. Finally, we measured the inhibitory activities of Thonzonium bromide against 3CLpro of SARS-CoV, MERS-CoV and HCoV-229E and found that it had the broad-spectrum inhibitory activity against the proteases of human coronaviruses. These results provide the possible mechanism of action of Thonzonium bromide, highlighting its potential efficacy against multiple human coronaviruses." @default.
• W4308743119 created "2022-11-15" @default.
• W4308743119 creator A5002855077 @default.
• W4308743119 creator A5004775159 @default.
• W4308743119 creator A5020302124 @default.
• W4308743119 creator A5037327997 @default.
• W4308743119 creator A5037857879 @default.
• W4308743119 creator A5064164171 @default.
• W4308743119 creator A5068428294 @default.
• W4308743119 creator A5081909934 @default.
• W4308743119 creator A5084203107 @default.
• W4308743119 date "2023-01-01" @default.
• W4308743119 modified "2023-09-27" @default.
• W4308743119 title "Discovery and mechanism of action of Thonzonium bromide from an FDA-approved drug library with potent and broad-spectrum inhibitory activity against main proteases of human coronaviruses" @default.
• W4308743119 cites W2007679990 @default.
• W4308743119 cites W2025649131 @default.
• W4308743119 cites W2025938842 @default.
• W4308743119 cites W2040184556 @default.
• W4308743119 cites W2052749821 @default.
• W4308743119 cites W2071055678 @default.
• W4308743119 cites W2099887607 @default.
• W4308743119 cites W2102469876 @default.
• W4308743119 cites W2157942235 @default.
• W4308743119 cites W2284201926 @default.
• W4308743119 cites W2407040666 @default.
• W4308743119 cites W2418376386 @default.
• W4308743119 cites W2557364141 @default.
• W4308743119 cites W2592515669 @default.
• W4308743119 cites W2761569424 @default.
• W4308743119 cites W2792420878 @default.
• W4308743119 cites W3003668884 @default.
• W4308743119 cites W3004243871 @default.
• W4308743119 cites W3004280078 @default.
• W4308743119 cites W3004318991 @default.
• W4308743119 cites W3009885589 @default.
• W4308743119 cites W3011701533 @default.
• W4308743119 cites W3015608194 @default.
• W4308743119 cites W3018023298 @default.
• W4308743119 cites W3020300207 @default.
• W4308743119 cites W3021411957 @default.
• W4308743119 cites W3036865135 @default.
• W4308743119 cites W3044143894 @default.
• W4308743119 cites W3046385872 @default.
• W4308743119 cites W3046597137 @default.
• W4308743119 cites W3046737617 @default.
• W4308743119 cites W3080677494 @default.
• W4308743119 cites W3083310584 @default.
• W4308743119 cites W3092541273 @default.
• W4308743119 cites W3122899941 @default.
• W4308743119 cites W3125622076 @default.
• W4308743119 cites W3130199871 @default.
• W4308743119 cites W3131227142 @default.
• W4308743119 cites W3133782701 @default.
• W4308743119 cites W3141176229 @default.
• W4308743119 cites W3157991090 @default.
• W4308743119 cites W3164970783 @default.
• W4308743119 cites W3182606802 @default.
• W4308743119 cites W3183900570 @default.
• W4308743119 cites W3189646261 @default.
• W4308743119 cites W3198561858 @default.
• W4308743119 cites W3199849883 @default.
• W4308743119 cites W3200155615 @default.
• W4308743119 cites W3203960425 @default.
• W4308743119 cites W3203993419 @default.
• W4308743119 cites W3208205965 @default.
• W4308743119 cites W3214271933 @default.
• W4308743119 cites W3214413850 @default.
• W4308743119 cites W4200047841 @default.
• W4308743119 cites W4225861618 @default.
• W4308743119 cites W4226157238 @default.
• W4308743119 cites W4284961864 @default.
• W4308743119 cites W4295901154 @default.
• W4308743119 doi "https://doi.org/10.1016/j.bioorg.2022.106264" @default.
• W4308743119 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36395603" @default.
• W4308743119 hasPublicationYear "2023" @default.
• W4308743119 type Work @default.
• W4308743119 citedByCount "2" @default.
• W4308743119 countsByYear W43087431192023 @default.
• W4308743119 crossrefType "journal-article" @default.
• W4308743119 hasAuthorship W4308743119A5002855077 @default.
• W4308743119 hasAuthorship W4308743119A5004775159 @default.
• W4308743119 hasAuthorship W4308743119A5020302124 @default.
• W4308743119 hasAuthorship W4308743119A5037327997 @default.
• W4308743119 hasAuthorship W4308743119A5037857879 @default.
• W4308743119 hasAuthorship W4308743119A5064164171 @default.
• W4308743119 hasAuthorship W4308743119A5068428294 @default.
• W4308743119 hasAuthorship W4308743119A5081909934 @default.
• W4308743119 hasAuthorship W4308743119A5084203107 @default.
• W4308743119 hasBestOaLocation W43087431191 @default.
• W4308743119 hasConcept C142724271 @default.
• W4308743119 hasConcept C159110408 @default.
• W4308743119 hasConcept C181199279 @default.
• W4308743119 hasConcept C182220744 @default.
• W4308743119 hasConcept C185592680 @default.
• W4308743119 hasConcept C202751555 @default.
• W4308743119 hasConcept C2776120743 @default.
• W4308743119 hasConcept C2776714187 @default.
• W4308743119 hasConcept C2777283782 @default.

• next